Attorney Docket No. 119620.0154

Response to Office Action mailed April 30, 2008

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

1. (currently amended) A microfluidic device for solid phase extraction of nucleic acids

from samples, said microfluidic device comprising

a body structure provided with a microchannel and an inlet port and an outlet port,

wherein said inlet port and outlet port are formed on an exterior surface of said body structure

and are in fluid communication with said microchannel, said microchannel having an interior

surface and a first and second end; and

a sol-gel matrix that spans a cross sectional dimension of the microchannel, wherein the

nucleic acids bind to the sol-gel matrix.

2. (original) The microfluidic device of claim 1 wherein the sol-gel matrix further comprises

silica particles.

The microfluidic device of claim 1 or 2 wherein the device further comprises a 3. (original)

reaction chamber in fluid communication with the microchannel and the outlet port.

4. (original) The microfluidic device of claim 1 wherein the sol-gel matrix is prepared using

tetramethoxy orthosilicate monomers.

The microfluidic device of claim 1 or 2 wherein the sol-gel matrix comprises 5. (original)

pores having a diameter selected from the range of about 0.1 μm to about 10 μm.

2

119620.00154/35885661v.1

Attorney Docket No. 119620.0154

Response to Office Action mailed April 30, 2008

The microfluidic device of claim 5 wherein the average diameter of the sol-gel 6. (original)

matrix pores is about 1 μm to about 5 μm.

7. (original) The microfluidic device of claim 5 wherein the sol-gel matrix is bound to the

interior surface of the microchannel.

The microfluidic device of claim 7 wherein the sol-gel matrix fills the 8. (original)

microchannel from the first end to the second end.

9. (currently amended) A method of extracting nucleic acids from a biological sample said

method comprising

contacting said sample with a chaotropic agent;

providing a microcolumn containing a sol-gel matrix having a cross sectional dimension

ranging from about 50 mm<sup>2</sup> to about 100 μm<sup>2</sup>;

loading the sample onto a the microcolumn under conditions conducive for nucleic acid

binding to the column, wherein said column comprises a sol-gel matrix having a cross sectional

dimension ranging from about 50 mm<sup>2</sup> to about 100 µm<sup>2</sup>;

washing the matrix with a solvent; and

releasing the bound nucleic acid from the column.

10. (original) The method of claim 9 wherein the sol-gel matrix has a cross sectional dimension

ranging from about 24 mm<sup>2</sup> to about 100 μm<sup>2</sup>.

3

Attorney Docket No. 119620.0154

Response to Office Action mailed April 30, 2008

11. (original) The method of claim 10 wherein the nucleic acid is DNA.

12. (original) The method of claim 10 wherein the sol-gel matrix comprises pores having a

diameter selected from the range of about 0.1 µm to about 10 µm.

13. (original) The method of claim 9 wherein the nucleic acid is released from the column by

washing with a buffer that is compatible with PCR reactions

14. (original) A nucleic acid processing system comprising

a base provided with a first and second microchannel, said first and second

microchannels each having an interior surface and a first and second end;

a first port formed on an exterior surface of said base and in fluid communication with

the first end of said first microchannel;

a second port formed on an exterior surface of said base and in fluid communication with

both the second end of the first microchannel and the first end of the second microchannel;

a third port formed on an exterior surface of said base and in fluid communication with

the second end of said second microchannel; and

a sol-gel matrix that spans a cross sectional dimension of the first microchannel, wherein

the nucleic acids bind to the sol-gel matrix.

15. (original) The nucleic acid processing system of claim 14 wherein the base further

comprises a reaction chamber in fluid communication with the first and second microchannel

and the second port.

4

Attorney Docket No. 119620.0154

Response to Office Action mailed April 30, 2008

16. (original) The nucleic acid processing system of claim 14 wherein the first, second and third

ports are each formed on the same exterior surface of the base.

17. (original) The nucleic acid processing system of claim 14 wherein said device further

comprises pumping means in communication with said reaction chamber to regulate fluid flow to

and from the reaction chamber.

18. (original) The nucleic acid processing system of claim 14 wherein said device further

comprises pumping means in communication with the first and second microchannels that

regulates fluid flow through the first and second microchannels.

19. (original) The nucleic acid processing system of claim 18 wherein the wherein the sol-gel

matrix comprises pores having a diameter selected from the range of about 0.1 µm to about 10

μm.

20. (original) The nucleic acid processing system of claim 19 wherein the sol-gel matrix is

bound to the interior surface of the first microchannel.

21. (original) The nucleic acid processing system of claim 18 wherein said second

microchannel is provided with reagents for analyzing nucleic acids.

5

U.S. Serial No.: 10/517,980 Attorney Docket No. 119620.0154

Response to Office Action mailed April 30, 2008

22. (original) The nucleic acid processing system of claim 18 wherein the base is a microfluidic device.